CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed
Drug / intervention
thalidomidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00004276
NCT00004276Phase 2Completed
CompareCT.gov

Phase II Placebo Controlled Study of Thalidomide in Patients With Mycobacterial and HIV Infections

National Center for Research Resources (NCRR)·interventional·Posted Oct 19, 1999·Updated Jun 24, 2005

In Brief

A Phase 2 clinical trial evaluating thalidomide for HIV Infections and 2 related conditions. Completed.

Detailed Summary

OBJECTIVES: I. Evaluate whether thalidomide modulates toxic host inflammatory responses in patients receiving antitubercular therapy. II. Evaluate whether thalidomide modifies tumor necrosis factor-mediated toxic symptoms of HIV and mycobacterial infections, and limits progression of HIV immunodeficiency. III. Evaluate whether thalidomide stimulates immunity in patients with HIV and/or mycobacterial infections.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections, Mycobacterium Infections, Tuberculosis
Countries--
CollaboratorsNational Institute of Allergy and Infectious Diseases (NIAID), Rockefeller University

Timeline

Phase 2CompletedFinished
19901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 19, 1999
Enrollment StartSep 1, 1990
Study CompletionJun 1, 1999
TodayJul 2, 2026
Posted 26.7 years ago

Interventions

thalidomidedrug